11 November 2015 - Roche announced today that the U.S. FDA approved Cotellic (cobimetinib) for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib).

For more details, go to: http://www.roche.com/media/store/releases/med-cor-2015-11-11.htm